According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become… [ Get More Details ]
Cancer patients in the U.S. experience greater survival gains than those in European countries, and the value of additional gains exceeds the additional cost of care in the U.S.
[ Get More Details ]
Following the current path, the colon cancer incidence rate will increase by 31.8% between 2003 and 2023 (447,000 people). If an alternative path is taken, there will be 17.7% (79,000… [ Get More Details ]